NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway

Core Insights - NeurAxis, Inc. has achieved a significant milestone with the implementation of a Category I CPT code for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, which is expected to enhance commercial clarity and patient access to care [1][2][3] Group 1: CPT Code Significance - The assignment of the Category I CPT code is a breakthrough for the widespread adoption of NeurAxis' IB-Stim® therapy, establishing a recognized coding and billing pathway [2][8] - This coding reflects broad clinical acceptance and meets the American Medical Association's criteria for clinical efficacy and standards of care [2] Group 2: Business Impact - The implementation of the CPT code is anticipated to strengthen NeurAxis' business foundation by improving payer alignment and scalability across health systems [3] - The company believes that this will accelerate patient access to care, support coverage expansion, and drive long-term revenue growth [3] Group 3: Company Overview - NeurAxis focuses on neuromodulation therapies for chronic conditions in both children and adults, with its IB-Stim® technology FDA cleared for specific gastrointestinal issues in patients aged 8 and older [5] - The company is conducting additional clinical trials for PENFS in various pediatric and adult conditions with significant unmet healthcare needs [5]